Search

The advent of new technology for geographical representation and spatial analysis of databases from different sectors offers a new approach to planning and managing the control of tropical diseases. This [...]

In the last decades, with little or no surveillance sleeping sickness has returned to alarming levels comparable to the early twentieth century. Sixty million people are considered at risk but only 3-4 million are under surveillance, yielding some 45 000 new cases annually. It is estimated that at least 300 000-500 000 people are presently infected. Despite the almost universal presence of the vector in sub-Saharan Africa and the existence of an animal parasite reservoir, it is technically feasible to control and eliminate the disease as a public health problem. The authors describe, step-by-step, a surveillance method based on the epidemiological status of the village and using several approaches ranging from passive to active surveillance. Co-ordinated by the WHO, such surveillance has been incepted in several countries. Epidemiological data is spatially linked to the village, whose geographical co-ordinates are collected using a Global Positioning Systems (GPS). Information is transmitted to WHO through internet. Data analysis and mapping is carried out using Geographical Information System (GIS) software and thematic maps are generated to illustrate epidemiological status. Examples from Central African Republic (CAR), Cameroon and Gabon illustrate the process and mapping. [ABSTRACT FROM AUTHOR]

The re-emergence of sleeping sickness as a major health problem in parts of Africa, combined with the new sources of financial support and provision of drugs means that an investigation of the cost-effectiveness of the different approaches is timely. There has been very little work done on the economics of controlling either form of sleeping sickness. This paper builds on work done for WHO by the authors on developing a framework for analysing the cost-effectiveness of different methods for surveillance in gambiense sleeping sickness. The framework has been used to build a spreadsheet which makes it possible to simulate the effects of controlling the disease at different prevalences, for example using mobile teams or various forms of fixed post surveillance and screening different proportions of the population in a year. Prices, control strategies, prevalence, sensitivity and specificity of tests are all variables which can be altered to suit different situations or investigate how different approaches perform. As new research is beginning to produce calculations of the burden of sleeping sickness, in terms of disability-adjusted life years (DALY) potentially averted by controlling the disease, it is possible to combine these DALY estimates with the analyses of cost-effectiveness undertaken in these exercises to look at the cost-utility of the work, both to compare different approaches and demonstrate that controlling sleeping sickness represents good value for money as an investment in health.

Sleeping sickness has long been known from descriptions by Arab merchants and slave traders. However it was not until 1901 that Forbes discovered the offending agent and 1903 that Bruce described the role of the tsetse fly. The basic epidemiological transmission cycle was described less than 10 years later. Although the main outline of the original model can still be considered as sound, subsequent research has greatly expanded our knowledge. Molecular biology has identified different parasites causing clinical forms of varying severity. Understanding of the antigenic variability to the parasite has also improved. While available data is still insufficient on the relationship between the vector and human being and the vector and the animal reservoir, the behavior of glossinae is well-documented. Current geographical information systems have promoted understanding of the distribution of the disease to enhance targeting of screening, treatment, and vector-control activities. To repeat the success achieved in controlling the disease in endemic countries in the 1960s, it will be necessary to develop new strategies based on this new knowledge.

African trypanosomiasis, or sleeping sickness, is a tropical disease caused by trypanosome parasites transmitted by tsetse flies. The focus of this paper is on the cost-effectiveness of alternative drug treatments for patients in the late stage of the disease. Melarsoprol has been used for many decades. More recently, eflornithine has been developed. It has fewer side effects and improves the overall cure rate. It is much more expensive than melarsoprol, however. The objective of the present cost-effectiveness is to identify the costs and benefits that would be involved in switching from melarsoprol to eflornithine in the treatment of late stage sleeping sickness. Benefits are expressed in lives saved as well as in disability adjusted life years (DALYs). The analysis is applied to the case of Uganda. The implications for affordability are also considered, by taking account of how the treatment costs would be shared between the national government, donors and patients. The baseline results indicate that melarsoprol treatment is associated with an incremental cost per life and DALY saved of $209 and $8, respectively. Each additional life saved by switching from melarsoprol alone to a combination of melarsoprol and eflornithine would cost an extra $1,033 per life saved, and an extra $40.9 per DALY gained. Shifting from this second alternative to treatment of all patients with eflornithine leads to an incremental cost per life saved of $4,444 and an incremental cost of $166.8 per DALY gained.

In order to study the sensitivity in vitro of Trypanosoma brucei gambiense to pentamidine, 5 x 10(4) parasites were exposed to 0, 0.1, 1.0, 2.0, 10, 100, 1000 and 10,000 micrograms/L of pentamidine isethionate for up to 10 d. The viability of parasites was determined each day by microscopy. Multiplication was retarded during continuous exposure to 2 micrograms/L. After 4 d no further multiplication took place, although the trypanosomes remained alive for another 3 d. The parasiticidal effect was more pronounced when higher concentrations were used; when exposed to 10 and 100 micrograms/L, all parasites were dead after 4 and 3 d, respectively. Despite exposure to 1000 micrograms/L, 74% of the parasites were still alive the next day. 10,000 micrograms/L killed all parasites within 24 h of exposure. Our results show that the time period of exposure to pentamidine plays a major role in determining the sensitivity in vitro of T. b. gambiense, and we suggest that prolonged exposure in vivo may be more important than attaining high but brief peak concentrations.

The investigators carried out a comparative evaluation of twelve or parasitological techniques used nowadays in the diagnosis of human trypanosomiasis and parasite isolation in the lymph fluid, blood and cerebro-spinal fluid (CSF). The tests were performed on 64 seropositive suspects selected with TESTRYP-CATT among 661 attendants examined at the Projet de Recherches Cliniques sur la Trypanosomiase (PRCT), Daloa, Côte-d'Ivoire. The study showed that the sensitivity of the different techniques varies between 17.2% (for CSF inoculation to Mastomys) and 84.5% (for the anion exchange centrifugation technique-mAECT). The classical techniques, says lymph fluid examination, direct blood examination and thick blood have a sensitivity of 58.6, 22.4 and 34.5% respectively. The most sensitive methods are lymph fluid examination, mAECT and double centrifugation of CSF (69%). The sensitivity increases up to 98.3% with the combination of two or three techniques. The combination of lymph fluid examination/mAECT/double centrifugation of CSF is either the most sensitive and the most suitable one for use in the field. The combination of lymph fluid examination and mAECT which detects 91.4% of the infected subjects is the most efficient. The authors discussed the results and recommended that similar study be done in field conditions to assess methods which either demonstrated better sensitivity and are more suitable for field use.

A case-control study was carried out in the Congo to define a scoring system based on a number of clinical and epidemiological criteria of African trypanosomiasis due to Trypanosoma brucei gambiense which could be used by peripheral health services to establish a diagnosis. The survey comprised 163 cases and 326 controls. Clinical signs and symptoms were fever, headache, pruritus and skin lesions due to scratching, diarrhoea, oedema, cervical adenopathies, sleep rhythm disturbances, changes in appetite, amenorrhoea or impotence, mental confusion, neurological signs, and other minor clinical disturbances. Other criteria were a history of previous trypanosomiasis and the presence of domestic animals in the home environment. Analysis of the results showed that neither a single criterion nor a group of criteria is pathognomonic for the disease. The selected criteria do not allow discrimination of sleeping sickness patients among suspected individuals who present themselves. A scoring system is therefore of little use at the peripheral level of health services, particularly when considering the additional workload involved. The low diagnostic value of these clinical signs and symptoms and other indicators in African trypanosomiasis stresses the difficulty in developing an early warning tool for an integrated control strategy in primary health care.

The Testryp CATT was performed on dried blood samples on filter-paper and on diluted blood using a microtechnique. This method was applied to both sample collection techniques and was evaluated in parallel with the classical Testryp CATT on whole blood, as described in the instructions provided with the reagents by the manufacturer. A total of 2087 people were tested; 453 samples were tested in the laboratory and 1634 during a field survey in 5 villages of a trypanosomiasis focus in Daloa, Côte d'Ivoire. This study has demonstrated that the Testryp CATT micromethod on either type of sample collection gives results comparable to the Testryp CATT on whole blood. The collection of dried blood samples on filter-paper can be performed by non-specialized staff in trypanosomiasis control programmes of the national health services. In addition, a flask of CATT reagent will allow testing of 6 times more people by the micromethod than by the classical whole-blood method. The micromethod is suitable in the implementation of programmes for the serological surveillance of populations at risk.

Described is an evaluation of the card agglutination test (Testryp CATT) applied to dried blood collected on filter-paper. The sensitivity of the test was compared for samples of diluted sera, whole blood and dried blood. Sera diluted 1:8 gave similar CATT results to those obtained with dried blood. The false negative rate was 5.8%, and test specificity, 100.0%. Use of CATT with samples of dried blood is recommended for screening populations at risk for trypanosomiasis in situations where specialized surveillance teams are not available to test sera or whole blood.

Authors are reporting results from 3 control-case surveys carried out in sleeping sickness foci in Cameroon, Central African Republic and Congo. HIV seroprevalence rates are comparable among sleeping sickness patients and trypanonegative control persons. These results lead towards the absence of inter-relationships between sleeping sickness and retroviral infection.

We describe the use of repetitive DNA probes to characterise the relationships between different stocks of African trypanosomes representing the subspecies of Trypanosoma brucei. Probes derived from the ribosomal RNA genes (coding region and nontranscribed spacer) and another repetitive DNA sequence were used to characterise trypanosome stocks by Southern blotting. Numerical taxonomy methods applied to the resulting restriction enzyme patterns were used to derive a dendrogram depicting the relationships between the stocks examined. We show that three groups of West African human infective stocks can be distinguished: firstly, a group containing exclusively T. b. gambiense; secondly, a group which is indistinguishable from animal isolates in West Africa; and thirdly, a single stock which is indistinguishable from East African T. b. rhodesiense. In addition, we observe that T. b. rhodesiense stocks from East Africa are indistinguishable from animal isolates from the same area. Finally, we show that a group of T. b. rhodesiense stocks, isolated from a 1978 sleeping sickness outbreak in Zambia, are probably derived from a single parasite strain, and that this strain is distinct from T. b. rhodesiense parasites from Kenya and Uganda.

A double-centrifugation technique for the detection of trypanosomes in samples of cerebrospinal fluid is described and evaluated. The results of the analysis of samples of cerebrospinal fluid from 128 patients with Trypanosoma brucei gambiense sleeping sickness from the Daloa area of Côte d'Ivoire, obtained using single centrifugation, are compared with those obtained using the new method. Double centrifugation is at least twice as sensitive as single centrifugation and results in an increase of 37% in the early detection of late-stage case of the disease. The technique is easily implemented under field conditions.

The authors are recording results of a clinical, parasitological and immunological sample survey about african human trypanosomiasis in the South Chad where old focus has been reexplored. In 1988 the situation ever remains as a problem in some areas (Tapol, Ranga) where high prevalence rates are found again.